Alchemab Therapeutics与 Eli Lilly and Company签署了价值 4.15亿美元的 ATLX-1282许可协议-动脉网

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company

CISION 等信源发布 2025-05-06 15:30



可切换为仅中文







- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism

- 与礼来公司达成新协议，授权ATLX-1282，这是一款针对神经退行性疾病的全新受体和机制的首创新药（IND就绪项目）

- Deal worth up to

- 交易价值高达

$415m

4.15亿美元

including upfront and downstream, plus royalties on top

包括上游和下游，再加上版税

- ATLX-1282 is the first programme out of Alchemab's entirely novel platform which generates and analyses millions of antibody sequences from resilient individuals

- ATLX-1282是Alchemab全新平台推出的首个项目，该平台从具有适应力的个体中生成并分析数百万个抗体序列

- Builds on existing discovery collaboration agreement with Lilly announced in

- 建立在与礼来公司此前宣布的现有发现合作协议的基础之上

January 2025

2025年1月

to discover, develop and commercialise up to five novel therapeutic candidates for ALS

发现、开发并商业化多达五种治疗ALS的新候选药物

CAMBRIDGE, England

剑桥，英格兰

，

May 6, 2025

2025年5月6日

/PRNewswire/ --

/美通社/ --

Alchemab Therapeutics (Alchemab),

阿尔凯玛治疗公司 (Alchemab)，

the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals

下一代生物制药公司，利用人类免疫进化的强大力量，从具有恢复力的个体中识别和开发天然存在的治疗性抗体。

, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab's first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.

今天宣布与礼来公司（Eli Lilly and Company，简称礼来）就Alchemab用于肌萎缩侧索硬化症（ALS）及其他神经退行性疾病的同类首创、处于IND准备阶段的ATLX-1282项目达成许可协议。

The transaction is worth up to a total of

该交易总额高达

$415m

4.15亿美元

, including an undisclosed upfront payment, potential discovery, development, and commercialisation payments and royalties. Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation..

，包括未披露的预付款、潜在的发现、开发和商业化付款以及专利使用费。根据协议条款，Alchemab 将在 Lilly 领导所有进一步的开发和商业化之前，将该项目推进至早期的 1 期临床试验。

Alchemab's unique platform uses state-of-the-art machine learning and AI to analyse the complexities of the human immune response and identify antibodies that are uniquely associated with resilience to untreatable diseases. This is achieved using over 6,000 carefully selected and highly curated patient samples across neurodegeneration, immunology, oncology and healthy aging.

阿尔凯马布的独特平台利用最先进的机器学习和人工智能技术，分析人类免疫反应的复杂性，并识别与对无法治愈的疾病具有抵抗力密切相关的抗体。该平台通过使用超过6000份精心挑选且高度策划的患者样本实现这一目标，这些样本涵盖神经退行性疾病、免疫学、肿瘤学和健康老龄化领域。

Weaving together lab-based protein science and biology with machine learning, human samples and proprietary data analysis, and leveraging Nvidia's supercomputer in .

将基于实验室的蛋白质科学和生物学与机器学习、人类样本和专有数据分析相结合，并利用Nvidia的超级计算机。

Cambridge

剑桥

, Alchemab has sequenced and analysed millions of antibody sequences to unveil novel targets and antibodies with unique mechanisms of action.

，Alchemab已经对数百万个抗体序列进行了测序和分析，以揭示具有独特作用机制的新靶点和抗体。

Through its research, Alchemab has identified an antibody in people with mutations that normally lead to frontotemporal dementia (FTD), but who remain well into old age. These samples were sourced from a collaboration with the Genetic Frontotemporal Initiative (GENFI) consortium, which has built the largest global cohort of FTD patients. .

通过其研究，Alchemab 在那些通常会导致额颞叶痴呆 (FTD) 的基因突变人群里发现了一种抗体，然而这些人却能健康地活到老年。这些样本来源于与遗传性额颞叶痴呆倡议组织 (GENFI) 联盟的合作，该联盟拥有全球最大规模的 FTD 患者队列。

Starting from the antibody sequence, Alchemab was able to identify the target and has subsequently demonstrated its importance in neuroprotection, and across multiple neurodegenerative conditions including ALS and FTD.

从抗体序列开始，Alchemab 能够识别目标，并随后证明了其在神经保护中的重要性，以及在包括肌萎缩侧索硬化症 (ALS) 和额颞叶痴呆 (FTD) 在内的多种神经退行性疾病中的重要性。

Alchemab's Chief Executive Officer,

Alchemab的首席执行官，

Jane Osbourn

简·奥斯本

, commented:

，评论道：

'As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in neurological conditions, they are ideally placed to speedily advance ATLX-1282 through the clinic, and maximise the potential to help patients. We believe this innovative programme has enormous promise and look forward to working with Lilly to bring this to fruition..

“作为我们高度创新平台的首个项目，这项合作对Alchemab而言具有里程碑意义。凭借礼来在神经疾病领域的深厚专业知识，他们能够迅速推动ATLX-1282通过临床试验，并最大化帮助患者的可能性。我们相信这一创新项目潜力巨大，并期待与礼来合作将其变为现实。”

'Today's announcement is also a tremendous endorsement for Alchemab's unique approach to drug discovery. Our revolutionary computational and wet lab-based workflow has enabled us to sift through millions of antibodies to identify this target. We think this is a powerful story demonstrating both the discovery of a novel antibody to treat neurogenerative diseases and the development of a unique platform which has great potential to provide innovative treatments across many disease settings.

“今天的公告也极大地认可了Alchemab独特的药物发现方法。我们革命性的计算和湿实验室工作流程使我们能够筛选数百万个抗体以确定这一目标。我们认为这是一个强有力的故事，展示了发现用于治疗神经退行性疾病的新型抗体，以及开发了一个有巨大潜力在多种疾病领域提供创新疗法的独特平台。

The transaction will support our work to progress our pipeline, which includes metabolic, immunology and oncology programmes, towards the clinic and we look forward to unveiling highly differentiated assets in these areas in due course.' .

该交易将支持我们推进包括代谢、免疫学和肿瘤学项目在内的研发管线走向临床的工作，我们期待在适当的时候展示这些领域中高度差异化的资产。

This transaction builds on a separate discovery collaboration agreement with Lilly announced in

这项交易建立在与礼来公司宣布的单独发现合作协议的基础上，

January 2025

2025年1月

to discover, develop and commercialise up to five novel therapeutic candidates for ALS.

发现、开发并商业化多达五种治疗ALS的新候选药物。

About Alchemab

关于Alchemab

Alchemab studies the natural antibody responses of individuals who are highly resilient to disease and identifies antibodies uniquely shared in the resilient groups and not seen in disease progressors. The targets to these antibodies are then identified and the antibodies developed into therapies for hard-to-treat diseases which do not have disease modifying approaches.

Alchemab研究了对疾病具有高度抵抗力的个体的自然抗体反应，确定了在抵抗力强的群体中独特共有而未在疾病进展者中出现的抗体。随后确定这些抗体的目标，并将抗体开发为用于治疗难以治愈且尚无疾病修饰方法的疾病的疗法。

Alchemab's platform integrates data mining and machine learning models of patient-derived immune responses with in vitro and in vivo drug discovery approaches to understand what keeps people well. The goal is to unlock nature's immunological response to disease and harness our highly evolved human immune system to find breakthrough drugs..

Alchemab的平台整合了数据挖掘和基于患者免疫反应的机器学习模型，并结合体外和体内药物发现方法，以了解是什么让人们保持健康。目标是揭示自然界对疾病的免疫反应，并利用我们高度进化的人类免疫系统来发现突破性药物。

Alchemab was founded in 2019 with seed funding from SV Health Investors, DCVC Bio and the Dementia Discovery Fund and has raised in excess of

阿尔凯马布公司成立于2019年，获得了来自SV Health Investors、DCVC Bio和痴呆症发现基金的种子资金，并已筹集超过

$80 million

8000万美元

to date from a blue-chip syndicate of specialist investors which also includes RA Capital, Lightstone Ventures and Camford Capital. The company is headquartered in

迄今为止，来自一个蓝筹财团的专项投资者，其中包括RA Capital、Lightstone Ventures和Camford Capital。该公司总部位于

London, UK

英国伦敦

with labs in

拥有实验室

Cambridge

剑桥

, UK.

，英国。

在

January 2025

2025年1月

, Alchemab announced an agreement with Eli Lilly and Company.

Alchemab 宣布与礼来公司达成协议。

Under the terms of the agreement, Alchemab will collaborate with Lilly to discover, develop and commercialise up to five novel therapeutic candidates for amyotrophic lateral sclerosis (ALS). Alchemab received an undisclosed upfront payment and is eligible to receive discovery, development and commercialisation milestone payments, plus royalties. .

根据协议条款，Alchemab将与Lilly合作，发现、开发并商业化多达五种治疗肌萎缩侧索硬化症（ALS）的新型候选药物。Alchemab获得了未公开的首付款，并有资格获得发现、开发和商业化里程碑付款，以及特许权使用费。

About amyotrophic lateral sclerosis (ALS)

关于肌萎缩侧索硬化症 (ALS)

ALS, also known as

肌萎缩侧索硬化症，也称为

Lou Gehrig's

卢·格里克氏病

disease, is a rare and terminal neurodegenerative disease for which there is no known cure. Early symptoms of ALS include stiff muscles, muscle twitches, gradual increasing weakness, and muscle wasting that results in the progressive loss of motor neurons that control voluntary muscles, leading to difficulties in speaking, swallowing, walking, and breathing.

疾病，是一种罕见且致命的神经退行性疾病，目前尚无已知的治愈方法。ALS 的早期症状包括肌肉僵硬、肌肉抽搐、逐渐加重的无力感，以及肌肉萎缩，导致控制随意肌的运动神经元逐渐丧失，进而引发说话、吞咽、行走和呼吸困难。

The average survival from onset to death is two to four years, though this can vary, and about 10% of those affected survive longer than ten years.

从发病到死亡的平均生存期为两到四年，尽管这可能会有所不同，大约10%的患者存活时间超过十年。

[1]

。

For more information, visit

欲了解更多信息，请访问

www.alchemab.com/

[1]

Long‐term survival in amyotrophic lateral sclerosis: A population‐based study - Pupillo - 2014 - Annals of Neurology - Wiley Online Library

肌萎缩侧索硬化症的长期生存率：一项基于人群的研究 - Pupillo - 2014 - 神经病学年鉴 - Wiley在线图书馆

SOURCE Alchemab Therapeutics